pharmaphorum

This Tuesday, #GSK has pulled out of Wave Life Sciences’ #RNA-editing programme for alpha-1 antitrypsin deficiency, just over three years after paying $170 million upfront for rights to the candidate. In other news today, #NovoNordisk’s #CagriSema has outperformed #Ozempic in a head-to-head diabetes trial, prompting the company to consider additional regulatory filings beyond its existing obesity submission. Meanwhile, #AstraZeneca has hit a regulatory setback in the US after the FDA rejected its self-injected formulation of #lupus drug #Saphnelo, despite the therapy recently winning approval in Europe. Elsewhere, Sanofi has been found in breach of the UK #pharma industry code for disparaging #Pfizer’s #RSV #vaccine in a 2024 newspaper article, and the UK government has announced plans to cover travel costs for children with cancer attending medical appointments from 2027.

🎙️ In today’s news https://lnkd.in/epS2jdQn : - #UCB gets an EU recommendation for the first therapy for thymidine kinase 2 deficiency (TK2d), plus other #CHMP decisions. - The #FDA has started accepting requests to participate in its #PreCheck pilot programme, promising rapid reviews of new #manufacturing facilities. - The FDA has turned down #Pharming's attempt to broaden the label of Joenja for rare #immunodeficiency disorder #APDS, so it can be used in younger patients. - #Sanofi has reported positive phase 3 results with venglustat in #Gaucher disease, but the drug missed the mark in a #Fabry disease trial. - #EliLilly has revealed the fourth new manufacturing site in its $27 billion capital investment spree in the US - a $3.5bn facility in Pennsylvania.

Discover more about how #ExpertDirectedAI transforms information into action: learn more about why the future of #AI in #biopharma belongs to leaders who combine #humaninsight with #machinescale in a new #whitepaper from Lumanity. https://lnkd.in/eHTvdnw3

Missed our contributed #thoughtleadership from last week? Failed to sink your teeth into the latest features on equitable #AI, creative #pharmamarketing, and improving #cancer outcomes in sub-Saharan #Africa? 📰 👓   Here's a reminder of pharmaphorum #pharmareads from 26th to 30th January!   ➡️ Closing the digital gap: Paid media’s essential role in omnichannel strategy By weaving paid media into the full engagement funnel, pharmaceutical brands can bridge critical communication gaps, deliver personalised experiences, and accelerate product adoption and memorisation. https://lnkd.in/ddwaggZu   ➡️ Meeting the growing demand for animal-free medicines A recent study published in the Postgraduate Medical Journal reported that 43.2% of respondents indicated a preference to forgo medications containing animal products, even in the absence of a suitable alternative. https://lnkd.in/dmej3aM2   ➡️ The quiet evolution taking place in paediatric imaging It’s also essential to remember that children are not simply “small adults” and require imaging approaches tailored to their unique anatomy and physiology.  https://lnkd.in/d9ysFyQr ➡️ AI's promise, biotech's peril: How unequal access to computing power threatens medical breakthroughs The message for policymakers, investors, and industry leaders is clear: ensuring equitable AI access isn't about fairness – it's about maximising our collective shot at breakthrough therapies. https://lnkd.in/d6TRqz_U   ➡️ Changing how the world finds new medicines: Physics modelling Finding treatments for diseases afflicting humanity often proceeds at a crawl, leaving many serious medical needs unmet. Solving this problem requires a fundamentally novel approach to finding drugs. https://lnkd.in/dT3a-aG7   ➡️ When advertising educates: How interactive creative empowers patients and providers Interactive formats allow brands to surface clinical research in concise, digestible ways that support ongoing physician education while delivering content in a personalised, one-to-one manner. https://lnkd.in/dJx5Qi33   ➡️ Improving breast cancer outcomes in sub-Saharan Africa The key activities of AMPATH, through grant funding from The Pfizer Foundation, will be to engage regional health leaders in Kenya to revise national breast cancer guidelines and develop new education resources. https://lnkd.in/dyfjY-_F

In this week’s Top Stories, #AstraZeneca deepened its ties with #China, pledging $15 billion in #investment and signing a big $18.5 billion alliance with #CSPCPharma for #obesity and #diabetes drugs. Meanwhile, users of #weightlosstherapies based on #GLP1 agonists were warned to be aware of a rare complication, #pancreatitis, which can be severe. And 2025 was a challenging year for the #UKbiotech sector, but it ended the year with signs of "renewed confidence," the #BIA industry body said. Elsewhere last week, #CMS's #Medicare #price ]negotiations started round three, the US federal government naming the next 15 big-selling medicines. In other news, the #WHO announced that the UK lost its #measles elimination status, due to a spike in cases in 2024 and a fall in #vaccination coverage. All this and more at https://pharmaphorum.com

This Friday, we report on how users of #weightlosstherapies based on #GLP1 agonists have been warned to be aware of a rare complication, #pancreatitis, which can be severe. In other news today, #AstraZeneca has deepened ties with #China, pledging $15 billion in #investment and signing a big $18.5 billion alliance with #CSPCPharma for #obesity and #diabetes drugs. Elsewhere, concerns about #efficacydata in the main trial behind the approvals of #CSLVifor and #Amgen's Tavneos have triggered a review in the #EU. Meanwhile, #SummitTherapeutics has moved ahead in the race to bring a therapy targeting both #VEGF and #PDL1 to market, after the #FDA started a review of its ivonescimab drug for #lungcancer. And #AgomAb, #SpyGlass, and #Veradermics have all set the terms for their #IPOs this week, looking to raise somewhere between around $150 million and $200 million. As we head into the weekend, check out our long reads from today: learn how interactive #CTV and cross-screen #creative formats make it possible to embed #educational elements directly into the #advertising experience; and learn how #AMPATH through funding from #ThePfizerFoundation is helping to improve #breastcancer outcomes in #Kenya. There’s also a new #video from #JPMorganHealthcareconference: learn more about #allogeneiccelltherapy from Brian Culley of Lineage Cell Therapeutics. Interested in regulatory changes and global policy updates? Check out our #SpotlightOn Policy page, for the most recent updates in US, EU, UK #policy, and beyond. All this and more at https://pharmaphorum.com

🎙️ In today’s news https://lnkd.in/epS2jdQn : - Users of #weightlosstherapies based on #GLP1 agonists have been warned to be aware of a rare complication, #pancreatitis, that can be severe. - AstraZeneca deepens ties with #China, pledging $15bn in #investment and signing a big $18.5bn alliance with CSPC Pharmaceutical Group for #obesity and #diabetes drugs. - Concerns about #efficacydata in the main trial behind the approvals of Amgen and CSL Vifor's Tavneos have triggered a review in the #EU. - Summit Therapeutics, Inc. moves ahead in the race to bring a #VEGFxPDL1 drug to market, after the #FDA started a review of ivonescimab in #lungcancer. - Agomab, SpyGlass Pharma, Inc., and Veradermics have all set the terms for their #IPOs this week, looking to raise somewhere between around $150m and $200m.

This Thursday, #RogerPerlmutter's new #cancer #biotech #Eikon has priced its #IPO, looking to raise up to $318 million and achieve a $900 million-plus valuation. Elsewhere, #Halozyme has expanded its portfolio of #drugdelivery technologies for a second time in only a few months with the #acquisition of #SurfBio for up to $400 million, and US digital physical therapy specialist #SwordHealth has bought its competitor #KaiaHealth for $285 million, positioning it for expansion in #Europe. In other news today, the FDA has started a priority review of #Otsuka's triple-acting drug for #ADHD, setting up a decision on the first-in-class drug in July, while #Tenpoint is set to join the US market for drugs to treat #presbyopia, taking on rival therapies from #AbbVie, #Orasis, and #LENZ with a dual-acting rival. Our longer reads today consider how industry can find new medicines with physics-based #molecularmodelling in a Q&A with Verseon. Or take a look at why #AI’s promise could spell #biotech’s peril. And turn again to our Equity & Sustainability #DeepDive issue for an exploration of the possible role of #progesterone in #fertilitycare and early pregnancy support. Interested in #regulatory changes and global policy updates? Check out our #SpotlightOn Policy page, for the most recent updates in US, EU, UK #policy, and beyond. All this and more at https://pharmaphorum.com

🗞️ In today’s news https://lnkd.in/epS2jdQn : - Roger M. Perlmutter's new #cancer #biotech Eikon Therapeutics has priced its #IPO, looking to raise up to $318m and achieve a $900m-plus valuation. - Halozyme, Inc. has expanded its portfolio of #drugdelivery technologies for a second time in a few months with the #acquisition of Surf Bio for up to $400m. - US #digitalphysicaltherapy specialist Sword Health has bought its competitor Kaia Health for $285m, positioning it for expansion in #Europe. - The #FDA has started a priority review of Otsuka Pharmaceutical Co., Ltd.'s triple-acting drug for #ADHD, setting up a decision on the first-in-class drug in July. - Tenpoint Therapeutics, Ltd. is set to join the US market for drugs to treat #presbyopia, taking on rival therapies from AbbVie, Orasis Pharmaceuticals, and LENZ Therapeutics with a dual-acting rival.

The intention with #STEMAI is to go beyond KPIs to deliver deeper insights into what truly drives performance and outcomes while fuelling #IntelligentCommercialization. In a new sponsored #video from Inizio Ignite, STEM experts Timothy Luxford, Chloe Stockwell-Clark, and Adam Boucher explain what brought the STEM AI vision to life, the importance of #personalisation in terms of transforming #fieldteam performance, and how STEM AI can help enhance partnership with clients. https://lnkd.in/eiNJqz9A